That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Atrial fibrillation (AF) is the most common cardiac arrhythmia and predisposes patients to stroke and systemic embolism. Vitamin K antagonists have been the only available oral anticoagulants for ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Among patients with atrial fibrillation, there is an unmet need for effective anticoagulation that prevents stroke but incurs a lower risk of bleeding than direct-acting oral anticoagulants.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Prescribing anti-clotting medications to adults younger than age 65 who have atrial fibrillation (AFib ... People who take an anticoagulant medicine double their risk of an internal bleed if ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.